Engineered immune cells battle blood cancers after transplant
NCT ID NCT06704152
Summary
This study is testing a new cellular therapy called BSB-1001 in adults with certain blood cancers (AML, ALL, or MDS) who are receiving a stem cell transplant from a donor. The main goals are to see if the treatment is safe and if it helps prevent the cancer from coming back after the transplant. Researchers will give patients modified immune cells designed to target cancer cells and monitor them closely for side effects and cancer recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Washington University at St Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.